Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

This is a paid FN Media promotional article surveying the CNS/brain cancer therapeutics space; ACAD is not the subject and made no new disclosure in it. The only ACAD content is a recap of a previously announced USPTO Notice of Allowance for a patent covering weight-banded dosing of trofinetide in Rett syndrome, expected to extend U.S. protection through March 28, 2041. The piece is primarily a promotional vehicle for NeOnc Technologies (NTHI), which paid $2,500 for the coverage, plus brief recaps of NBIX, AVXL, and MRK news.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.